Great progress has been made in the prevention and treatment of gynecological tumors in recent years, especially with immunotherapy becoming a powerful clinical cancer treatment strategy. However, there is still a lack of effective therapeutic methods for advanced disease, and the clinical results of immunotherapy are heterogeneous among patients, which seriously threatens women's health. Therefore, it is necessary to identify effective biomarkers for the early screening of cancer patients and to promote the development of precision therapy and immunotherapy. In addition, molecular-targeted anticancer therapies are constantly emerging, but their application is limited due to the lack of effective strategies to evaluate targeted drugs. Biomarkers that can reliably identify patients who are most likely to benefit from specific therapeutics are needed to evaluate these novel therapeutics and accelerate drug development. These biomarkers can be of different types, such as host genome factors, serum proteins, and nucleic acids (DNA or RNA molecules) in tumor cells and their microenvironment. Identification of ideal biomarkers can help gynecological cancer patients achieve better treatment goals and bring clinical benefits.
In the past decade, a variety of tumor biomarkers have been verified and widely used in clinics. However, new strategies still need to be developed to improve the efficiency and accuracy of cancer treatment by identifying more reliable biomarkers. Multi-omics, proteomics, oncomics, genomics, and other emerging methods have been applied in the identification of tumor cell-specific markers for early cancer diagnosis and immunotherapy. Identifying multiple immune checkpoint markers is crucial to developing therapeutic targets and will have a great impact on personalized medicine.
The purpose of this Research Topic is to explore novel diagnostic and prognostic biomarkers to screen patients with gynecological cancer in its early stage and to promote the development of precision medicine and immunotherapy. We welcome submissions of Original Research, Reviews, Hypothesis and Theory, Opinions, and Clinical Trials, focusing on but not limited to the following topics:
1. Identification and application of diagnostic and prognostic biomarkers for gynecological tumor
2. Identification and application of biomarkers for predicting recurrence and metastasis of gynecological tumors
3. Identification and application of cell type-specific biomarkers for gynecological tumor
4. Temporal and spatial heterogeneity of biomarkers and their regulation mechanism
5. Tumor immune microenvironment phenotype related biomarkers for gynecological tumors
6. Novel methods to improve the accuracy in identifying biomarkers of gynecological tumors
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Great progress has been made in the prevention and treatment of gynecological tumors in recent years, especially with immunotherapy becoming a powerful clinical cancer treatment strategy. However, there is still a lack of effective therapeutic methods for advanced disease, and the clinical results of immunotherapy are heterogeneous among patients, which seriously threatens women's health. Therefore, it is necessary to identify effective biomarkers for the early screening of cancer patients and to promote the development of precision therapy and immunotherapy. In addition, molecular-targeted anticancer therapies are constantly emerging, but their application is limited due to the lack of effective strategies to evaluate targeted drugs. Biomarkers that can reliably identify patients who are most likely to benefit from specific therapeutics are needed to evaluate these novel therapeutics and accelerate drug development. These biomarkers can be of different types, such as host genome factors, serum proteins, and nucleic acids (DNA or RNA molecules) in tumor cells and their microenvironment. Identification of ideal biomarkers can help gynecological cancer patients achieve better treatment goals and bring clinical benefits.
In the past decade, a variety of tumor biomarkers have been verified and widely used in clinics. However, new strategies still need to be developed to improve the efficiency and accuracy of cancer treatment by identifying more reliable biomarkers. Multi-omics, proteomics, oncomics, genomics, and other emerging methods have been applied in the identification of tumor cell-specific markers for early cancer diagnosis and immunotherapy. Identifying multiple immune checkpoint markers is crucial to developing therapeutic targets and will have a great impact on personalized medicine.
The purpose of this Research Topic is to explore novel diagnostic and prognostic biomarkers to screen patients with gynecological cancer in its early stage and to promote the development of precision medicine and immunotherapy. We welcome submissions of Original Research, Reviews, Hypothesis and Theory, Opinions, and Clinical Trials, focusing on but not limited to the following topics:
1. Identification and application of diagnostic and prognostic biomarkers for gynecological tumor
2. Identification and application of biomarkers for predicting recurrence and metastasis of gynecological tumors
3. Identification and application of cell type-specific biomarkers for gynecological tumor
4. Temporal and spatial heterogeneity of biomarkers and their regulation mechanism
5. Tumor immune microenvironment phenotype related biomarkers for gynecological tumors
6. Novel methods to improve the accuracy in identifying biomarkers of gynecological tumors
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
